RNA respiratory syncytial virus vaccines
US6428324B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | May 24, 2000 |
| Grant date | Aug 6, 2002 |
| Priority date | — |
| Expiry date | May 24, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/002
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A vector comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter is described. Such vector may be used to produce an RNA transcript which may be used to immunize a host, including a human host, to protect the host against disease caused by paramyxovirus, particularly respiratory syncytial virus, by administration to the host. The RNA transcript may be formed by linearization of the vector through cleavage at a unique restriction site in a plasmid vector and then transcribing the linear molecule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.